Kailera Therapeutics Prices IPO at $16, Aims for $625M

IPO Pricing and Capital Raise

Kailera Therapeutics Inc. (KLRA), a biotechnology firm specializing in obesity treatments, has priced its initial public offering at $16.00 per share. The company is offering 39,062,500 shares of common stock, with an expected $625.0 million in gross proceeds before underwriting discounts and offering expenses.

Market Debut Details

The stock is scheduled to begin trading on the Nasdaq Global Select Market under the ticker KLRA on April 17, 2026. The offering is anticipated to close on April 20, 2026, contingent upon customary closing conditions. Underwriters have a 30-day option to purchase up to 5,859,375 additional shares.

Offering Managers and Regulatory Status

The offering is managed by a team of joint book-runners including J.P. Morgan, Jefferies, and Leerink Partners. The U.S. Securities and Exchange Commission declared the company's S-1 registration statement effective on April 16, 2026. All shares offered are being sold directly by Kailera.

Summary

This IPO marks a significant capital injection for the Waltham-based company to advance its clinical-stage programs. The market's reception to KLRA's debut will be a key event for investors monitoring the biotechnology sector.

FAQ

Q: What is Kailera Therapeutics' IPO price?
A: The IPO is priced at $16.00 per common share.

Q: When will KLRA stock start trading?
A: Trading is set to begin on the Nasdaq on April 17, 2026.

Source: Investing.com